SURYAPHARM

Surya Pharmaceutical Limited has submitted to the Exchange the Standalone Financial Results for the period ended March 31,2012.

Surya Pharmaceutical Limited has informed the Exchange that the Board of Directors of the Company held on July 07, 2012 approved the following: (1) The Board has appointed Mr. Bharat Bhushan Jain as Company Secretary & Compliance officer of the Company in place of Mrs. Sugandha Kukreja w.e.f. June 16, 2012.(2) Further, Mr. Sanjay Kumar Suroya, Nominee Director of IDBI has resigned from the Directorship of the Company w.e.f. July 05, 2012.

Alka Goyal has submitted to the Exchange, vide letter dated July 06, 2012 a copy of Disclosure pursuant to Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Alka Goyal has submitted to the Exchange, vide letter dated July 03, 2012 a copy of Disclosure pursuant to Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Rajiv Goyal has submitted to the Exchange, vide letter dated July 02, 2012 a copy of Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Rajiv Goyal has submitted to the Exchange vide letter dated June 28, 2012, a copy of Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Rajiv Goyal has submitted to the Exchange, vide letter dated June 27, 2012 a copy of Disclosure pursuant to Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Alka Goyal has submitted to the Exchange, vide letter dated June 26, 2012 a copy of Disclosure pursuant to Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Alka Goyal has submitted to the Exchange, vide letter dated June 25, 2012 a copy of Disclosure pursuant to Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 for invocation of pledged shares.

Alka Goyal has submitted to the Exchange, vide letter dated June 21, 2012 a copy of Disclosure pursuant to Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Rajiv Goyal has submitted to the Exchange, vide letter dated June 20, 2012 a copy of Disclosure pursuant to Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Alka Goyal has submitted to the Exchange, vide its letter dated June 20, 2012 a copy of Disclosure pursuant to Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Rajiv Goyal has submitted to the Exchange, vide its letter dated June 16, 2012 a copy of Disclosure pursuant to Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Alka Goyal has submitted to the Exchange, vide its letter dated June 15, 2012 a copy of Disclosure pursuant to Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Rajiv Goyal has submitted to the Exchange, vide its letter dated June 15, 2012 a copy of Disclosure pursuant to Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Rajiv Goyal has submitted to the Exchange, vide its letter dated June 16, 2012 a copy of Disclosure pursuant to Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Alka Goyal has submitted to the Exchange, vide its letter dated June 12, 2012 a copy of Disclosure pursuant to Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 for invocation pf pledged shares.

Alka Goyal has submitted to the Exchange, vide its letter dated June 07, 2012 a copy of Disclosure pursuant to Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Emm Bee Fincap Pvt. Ltd. has submitted to the Exchange, vide its letter dated June 06, 2012 a copy of Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Alka Goyal has submitted to the Exchange vide its letter dated June 04, 2012 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Rajiv Goyal has submitted to the Exchange, vide its letter dated June 01, 2012 a copy of Disclosure pursuant to Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Surya Pharmaceutical Limited has informed the Exchange that the management has decided not to pursue the appeal further against the impugned order dated January 09, 2012 passed by the whole time member of S.E.B.I. for claiming necessary exemption to convert outstanding 27,50,000 Zero Coupon Convertible Share Warrants into equity shares without making open offer under Regulation 3(2) of SEBI (Substantial Acquisition of shares and Takeover) Regulations -2011 and also for extension of Exercisable Date for conversion of the same. Consequently the Outstanding 27,50,000 Zero Coupon Convertible Share

Alka Goyal has submitted to the Exchange vide its letter dated June 01, 2012 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Alka Goyal has submitted to the Exchange, vide letter dated May 28, 2012 a copy of Disclosure pursuant to Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Alka Goyal has submitted to the Exchange, vide letter dated May 25, 2012 a copy of Disclosure pursuant to Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Emm Bee Fincap Pvt. Ltd. has submitted to the Exchange, vide letter dated May 25, 2012 a copy of Disclosure pursuant to Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Emm Bee Fincap Pvt. Ltd. has submitted to the Exchange, vide letter dated May 22, 2012 a copy of Disclosure pursuant to Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Alka Goyal has submitted to the Exchange, vide letter dated May 22, 2012 a copy of Disclosure pursuant to Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Alka Goyal has submitted to the Exchange, vide letter dated May 19, 2012 a copy of Disclosure pursuant to Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Rajiv Goyal has submitted to the Exchange, vide letter dated May 17, 2012 a copy of Disclosure pursuant to Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Surya Pharmaceutical Limited has informed the Exchange that Dr. R.K Gupta & Dr. H.B.L Vohra have resigned from the directorship of the Company.

Surya Pharmaceutical Limited has submitted to the Exchange the Standalone Financial Results for the period ended March 31,2012 alongwith the Limited Review Report.

Rajiv Goyal has submitted to the Exchange vide its letter dated April 30, 2012 a revised copy of Disclosure pursuant to Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Surya Pharmaceutical Limited has submitted to the Exchange vide its letter dated May 01 , 2012 a copy of Disclosure under Regulation 13(4), 13(4A) and 13(6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992.

Surya Pharmaceutical Limited has submitted to the Exchange vide its letter dated April 30 , 2012 a revised copy of Disclosure under Regulation 13(4), 13(4A) and 13(6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992.

Rajiv Goyal has submitted to the Exchange vide its letter dated May 01, 2012 a copy of Disclosure pursuant to Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Surya Pharmaceutical Limited has informed the Exchange that : (1) The Company has shifted its Registered Office from # 601, 6th Floor, Surya Kiran Building, 19, K.G Marg, Connaught Place, New Delhi - 110001 TO 1596 ,Floor 1st, Bhagirath Palace, Delhi with effect from April 27, 2012.(2) Dr. S.K.Yadav has been appointed as Additional Director of the company w.e.f. April 27, 2012..

Rajiv Goyal has submitted to the Exchange vide its letter dated April 26, 2012 a copy of Disclosure pursuant to Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Surya Pharmaceutical Limited has informed the Exchange that :- (1) The State Bank of India as the lead bank of the consortium of bankers of Surya Pharmaceutical Limited has referred the Company for restructuring of its debt to the Corporate Debt Restructuring Cell, Mumbai and the Company has been admitted by CDR Cell with the support of majority of lenders; (2) The Company has received Certificate of Suitability (COS) for Cefalexin Monohydrate from European Directorate for the Quality of Medicines (EDQM), in addition to already approved Cefixime. Further, the Company's Banur Plant has also bee

Surya Pharmaceutical Limited has informed the Exchange that the Company has shifted its Registered Office from # 911, 9th Floor, Surya Kiran Building, 19 K.G. Marg, Connaught Place, New Delhi - 110001 to # 601, 6th Floor, Surya Kiran Building, 19 K.G. Marg, Connaught Place, New Delhi - 110001 with effect from March 01, 2012..

Surya Pharmaceutical Limited has submitted to the Exchange the Standalone Financial Results along with Limited Review Report for the period ended December 31,2011.

Surya Pharmaceutical Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on February 11, 2012, Mr . Devinder Pal has resigned from the directorship of the Company. The Board has appointed Mr. Sanjay S. kumar as Nominee Director-IDBI Bank in place of Mr. Ashwani kumar Agarwal.

Surya Pharmaceutical Limited has submitted to the Exchange the Standalone Financial Results for the period ended September 30,2011.

Surya Pharmaceutical Limited has informed the Exchange that at the meeting of the Board of Directors of the Company held on November 12, 2011, Mr. Anil Arya & Mr. Abhishek Arya have resigned from the directorship of the Company w.e.f. November 12, 2011. The Board has appointed Mr. D.P. Singhal as Independent Additional Director of the Company.

Surya Pharmaceutical Limited has informed the Exchange that Mr. Rajansh Thukral has resigned from the post of Associate Director & Chief Company Secretary of the Company. In his place, Ms Sugandha Kukreja has joined as Company Secretary and she shall act as Compliance Officer of the Company.

Surya Pharmaceutical Limited has submitted to the Exchange a copy of Proceedings of Annual General Meeting of the Company held on September 30, 2011.

Surya Pharmaceutical Limited has informed the Exchange vide its letter dated August 18, 2011 regarding Compliance Under Clause 53 of the Listing Agreement.

Surya Pharmaceutical Limited has informed the Exchange that the Register of members and share transfer books of the Company shall remain closed from September 29, 2011 to September 30, 2011 for the purpose of Annual General Meeting to be held on September 30, 2011 and to determine the Members entitled to receive the final dividend for the year ended March 31, 2011.

Surya Pharmaceutical Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on August 13, 2011 considered the following : (1) Dr. M.L. Sharma has resigned from the directorship of the Company w.e.f. July 23, 2011. The Board has appointed Dr. R.K. Gupta as Independent Additional Director of the Company with immediate effect; (2) The Board of Directors of the Company has decided to mobilize funds through Fixed Deposits.

Surya Pharmaceutical Limited has informed the Exchange that the Board of Directors of the Company at their Meeting held on August 13, 2011 has recommended a dividend @ 15% (Re.0.15/- per share) on Equity Shares of Rs.1/- each for the financial year 2010-11 and the payment of Dividend will be made on or before October 29, 2011.